Abstract: Enhanced dermatological compositions are described herein using from about 21 to about 40 wt-% urea with antioxidant skin protectants suitable for the treatment of icthyosis, xerosis, severely dry skin, dermatitis, eczema, debridement and tissue suffering and other similar skin conditions.

Abstract: The present invention provides methods of slowing or inhibiting vascular smooth muscle (VSM) cell proliferation to slow the development or recurrence of atherosclerosis by contacting VSM cells with soluble epoxide hydrolase (sEH) inhibitors. Further, the methods of the invention can be used to slow or to inhibit vascular restenosis after angioplasty and the stenosis of vascular stents. Further, the methods of the invention can be used to slow or to inhibit the stenosis of hemodialysis grafts and other natural and synthetic vascular grafts.

Abstract: The present invention includes a method for increasing meat production while reducing fat in ruminant and non-ruminant animals and for increasing egg production in poultry and milk production in ruminant animals. The method includes mixing ingredients that include 190 proof ethanol in a concentration of about 9% by weight of a food supplement with clay and a nitrogen source such as urea to form the food supplement. The food supplement for ruminant animals additionally includes a condensed distiller's soluble fraction. The mixed ingredients are added to an animal feed such as corn. The animal feed and supplement are fed to an animal at least one per day.

Abstract: The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension.

Abstract: Topical composition that contains about 10 to about 50% by weight urea with respect to the total composition weight of the composition; and a topically effective amount of an anti-oxidant compatible with skin. Compositions containing vitamin E, vitamin C, vitamin D and green tea are described. Also described is a method of enhancing delivery of an anti-oxidant to the viable epidermis, including topically applying a composition of the invention to a skin surface of a mammal.

Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: Topical compositions which include urea and carbamide peroxide are described. Compositions having a pH in the acidic range, particularly in the range of about 2.5 to about 9 are also described. Methods for treating dermatological disorders using the composition are also described.

Abstract: The invention features a method of modulating SMN exon 7 expression in a subject by administering hydroxyurea to the subject.

Abstract: The invention relates to use of (a) compounds of phosphorus containing at least partly lipophilic organic radicals together with (b) urea and/or urea derivatives in selected quantity ratios of (a) to (b) as a soil additive for biologically controlling plant-parasitic soil nematodes by strengthening the correspondingly antagonistic soil potential, more particularly by strengthening the growth of antagonistic and/or nematicidal rhizosphere bacteria and/or corresponding mycorrhiza strains—and at the same time strengthening the growth of cultivated plants in soil. The multicomponent mixtures which strengthen bacterial growth are preferably introduced into the region of the plant roots in the form of an aqueous preparation using plant-compatible emulsifiers before and/or during plant growth. Components (a) and (b) are used in such quantity ratios that the ratio by weight of C to N is no higher than 6:1 and preferably no higher than 5:1.

Abstract: A composition in the form of an ultrafine oil-in-water emulsion in which the mean size of the oil globules ranges from 50 nm to 1000 nm containing a haloalkynyl derivative, preferably 3-iodo-2-propynyl butylcarbamate.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: Benzobicyclooctane compounds, their use in inhibiting cellular events involving TNF-&agr; and IL-8, and in the treatment of inflammation events in general; a combinatorial library of diverse bicyclooctanes and process for their synthesis as a library and as individual compounds.

Abstract: A gel preparation comprising urea, an acrylic acid polymer and a xanthan gum.

Abstract: Topical compositions which include urea and benzoyl peroxide are described. Compositions having a pH in the acidic range, particularly in the range of about 4 to about 9 are also described. Methods for treating dermatological disorders using the composition are also described.

Abstract: Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.

Abstract: The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula I wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

Abstract: A purpose of the present invention is to provide TNF-&agr; production inhibitors being useful as therapeutic agents for autoimmune diseases such as rheumatoid arthritis.

Abstract: Solid sanitizing compositions have advantages over corresponding liquids and powders. A solid sanitizing product can be contained within a plastic bottle with a label indicating that the contents have antimicrobial or deodorizing properties containing a non-flowable solid composition having greater than about 0.02 percent by weight antimicrobial compounds. The preferred solid sanitizing compositions consist essentially of an antimicrobial compound selected from the group consisting of quaternary ammonium salts, fatty amines and diamines, chlorhexidine gluconate, phenol, derivatives of phenol, parachloro metaxylenol and mixtures thereof, and between 0 and 99.98 percent by weight of a cleaning composition. The solid sanitizing compositions can be effectively used with solid dispensers. The solid dispensers have a bowl with a drain at the bottom and an upward pointing spray nozzle.

Abstract: The present invention comprises methods and compositions for use in inhibiting egg production by parasitic trematode worms comprising administering to an individual in need thereof an effective amount of an agent which transiently inhibits the influx of calcium through a cell membrane calcium channel. Inhibition of egg production in the worms ameliorates many of the symptoms and pathology related to infection by trematode related diseases, including Schistosomiasis. The methods can also effect disease transmission by reducing the number of eggs released into the environment available to continue the worm life cycle.

Abstract: The invention relates to novel bicyclic aromatic compounds which have the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

Abstract: Methods and pharmaceutical compositions employing a terfenadine metabolite and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof. Also included are methods and compositions employing a terfenadine metabolite, a leukotriene inhibitor, and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof.

Abstract: Medical devices, compositions and methods for treating or preventing atherosclerotic plaque rupture are disclosed. Specifically, medical devices that deliver to a treatment site metalloproteinase inhibitors (MMPI) are disclosed. The medical devices include catheters, guide wires, vascular stents, micro-particles, electronic leads, probes, sensors, drug depots, transdermal patches, and vascular patches. Representative MMPIs included zinc chelators, urea derivatives, caprolactone-based inhibitors, phoshoinamides, piperazines, sulfonamides, tertiary amines, carbamate derivatives, mercaptoalcohols, mecaptoketones, antimicrobial tertracyclines, non-antimicrobial tetracyclines, and derivatives and combinations thereof. In one embodiment a self-expanding vascular stent is coated with at least one MMPI and deployed at a site within an artery where vulnerable plaque has been identified.

Abstract: Disclosed are compositions of a novel astringent and keratolytic topical pharmaceutical base into which drugs can be incorporated such as for example an anti-pruritic drug and/or an anti-inflammatory drug.

Abstract: Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Abstract: The present invention is related to new vanilloid analogues containing resiniferatoxin pharmacophores, pharmaceutical compositions comprising such analogues, and their uses as vanilloid receptor agonists and potent analgesics. The present invention provides a pharmaceutical composition for treating acute, chronic, inflammatory or neuropathic pains or for treating bladder hypersensitivity.

Abstract: The invention is related to the treatment of prion-related diseases such as the transmissible spongiform encephalopathies (TSEs) in mammals by administering chaotropic agents to or inducing a hyperthermia state in the affected mammals.

Abstract: Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

Abstract: Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.

Abstract: An object of the present invention is to provide novel urea derivatives which have TNF-&agr; production inhibitory effects and are useful as therapeutic agents for various diseases, particularly as therapeutic agents for autoimmune diseases such as rheumatoid arthritis. The urea derivatives according to the present invention are compounds represented by the formula [I] and salts thereof. In the formula, R1 is H, alkyl, phenyl or a group of the formula [`I]; R2 is H, alkyl, carboxyl or ester thereof or the like; R3 and R4 are each H, alkyl, cycloalkyl or the like; R5 is H, alkyl, hydroxy or the like; R6 is a nitrogen aromatic heterocycle; and A1 and A2 are alkylene.

Abstract: The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease.

Abstract: A process is provided for both removing and controlling biofilms present in industrial cooling and process waters. The process provides a composition which includes the reaction products of an amino base, a formaldehyde, an alkylenepolyamine, and the ammonium salt of an inorganic or organic acid. The composition may be used to remove existing biofilms from process water equipment. Further, lower maintenance dosages may be used to maintain the equipment in a substantially biofilm-free condition.

Abstract: A skin care composition comprising. (a) a silicone-containing phase comprising cross-linked polyorganosiloxane polymer and silicone oil, wherein the composition comprises from about 0.1% to about 20% by weight of the combination of cross-linked polyorganosiloxane polymer and silicone oil, (b) from about 0.1% to about 20% by weight of an organic liquid crystal-forming amphiphilic surfactant, and (c) water; wherein the composition is in the form of an oil-in-water emulsion. The compositions of the invention provide improved skin feel, reduced greasiness/stickiness and faster absorption.

Abstract: Use of cathepsin S inhibitors for the treatment of an allergic condition, in particular an atopic allergic condition, more specifically for the treatment of hay fever, asthma, atopic dermatitis or a food allergy.

Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.

Abstract: This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using small molecule carbamates and ureas.

Abstract: The present invention relates to pharmaceutical compositions and methods of using pyrrolecarbonylimino derivatives to inhibit N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) enzyme activity, thereby effecting neuronal activities, inhibiting angiogenesis, and treating glutamate abnormalities, compulsive disorders, prostate diseases and cancers.

Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.

Abstract: Compounds characterized generally as propargyl glycine amino propargyl diol derivatives are useful for treatment of a disorder mediated by inhibiting plasma renin activity.

Abstract: The use of a physiologically innocuous ammonium compound and/or urea as an additive to an infant formula or a pap or for the preparation of a pharmaceutical composition for the prophylaxis of sudden infant death syndrome (SIDS) is disclosed as is also an infant formula or a pap which in addition to conventional ingredients contains a physiologically innocuous ammonium compound and/or urea. Futhermore, a method of preventing SIDS is disclosed, which method comprises administering to the infant an infant formula or a pap as indicated above, and a method for the prophylaxis of SIDS, wherein a pharmaceutical composition containing a physiologically innocuous ammonium compound and/or urea is administered to the infant or the appropriately selected or modified non-pathogenic, urease-producing bacteria are supplied to the gastrointestinal tract of the infant.

Abstract: A composition comprising urea and an N-substituted aminosulfonic acid. The composition may be used for the care, treatment and/or protection of human skin, mucous membranes and/or keratin fibers, in particular for moisturizing the skin and for the treatment of dry skin.

Abstract: Provided is a cosmetic composition, which comprises (A) at least one moisture retaining component selected from the group consisting of amino acids and salts thereof, pyrrolidonecarboxylic acid and salts thereof, lactic acid and salts thereof, urea and betaines; and (B) at least one sesquiterpene alcohol. This cosmetic composition exhibits high effects for alleviating the rough or moisture-lost skin and improving the skin condition such as dry skin or sensitive skin.

Abstract: This invention relates to a single phase emulsifiable concentrate composition comprising (a) between about 0.05 and about 25 wt. % of a biologically, fungicidally and/or herbicidally active aza compound; (b) between about 2 and about 40 wt. % of a lactam selected from the group of N-methyl pyrrolidone, N-methyl caprolactam, a C8 to C18 alkyl pyrrolidone, a C8 to C18 caprolactam and a mixture thereof; (c) between about 2 and about 20 wt. % of a moisture scavenging agent selected from the group consisting of a liquid molecularly hindered carbodiimide, a molecular sieve or a mixture thereof and (d) between about 10 and about 80 wt. % of a mixture of at least two non-ionic surfactants having an overall hydrophilic/lipophilic balance (HLB) above 7. The invention also relates to the stable oil-in-water (o/w) miniemulsions prepared from the above by dilution to between about 40 and about 99.99 wt. % water for a “pour on”, dip or spray solution useful in the treatment of animals or plants.

Abstract: A method for treating HIV infection in human beings comprising the step of measuring viremia, and if viremia is less than 50,000-100,00 copies per milliliter, administering a combination of compounds selected from the group consisting of hydroxyurea, and one or more reverse transcriptase inhibitors.

Abstract: A composition of matter and the method of making that provides a low pH acidic composition that is useful for destroying microorganisms that are undesirable and useful for destroying or reducing melanoma on human skin. The composition and method include sulfuric acid combined with distilled water and ammonium sulfate under at least 15 psi pressure in a pressurized container, all of which is heated to approximately 800° F. or more for at least 3 hours. The final cooled mixture is stabilized with 10 percent of the original mixture. The resultant composition is useful for preserving food, such as fresh fish, and for skin treatment of melanoma.

Abstract: Stabilizers for live vaccines and attenuated mono- or multivalent live vaccines, stabilized vaccines containig such stabilizers, and methods for preparing such vaccines, are disclosed. Said stabilizers for vaccines containing one or more attenuated live viruses include one or more components selected from each of the following groups: amino acids, disaccharides, polyalcohols and buffer solutions, with the proviso that one component selected from the disaccharide group is saccharose.

Abstract: The present application relates to novel ceramide compounds to their process of preparation and to their use in cosmetics or in pharmaceuticals, in particular for treating and caring for the skin, hair, nails and eyelashes.

Abstract: Enantiomerically enriched disubstituted tetrahydrofurans, tetrahydrothiophenes, pyrrolidines and cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i. e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. It has been determined that 5-lipoxygenase activity, oral availability, and stability in vivo (for example, glucuronidation rate) can vary significantly among the optical isomers of the disclosed compounds.

Abstract: A treatment for xerostomia, employing a composition having the active ingredient of carbamide peroxide. The carbamide peroxide compound contains urea and hydrogen peroxide. The hydrogen peroxide remains stable until the carbamide peroxide is applied to the mouth and contacts the water inherent therein. On contact, the hydrogen peroxide is freed from the urea, allowing the hydrogen peroxide to react within the mouth. The resulting chemical and mechanical reaction stimulates saliva within the mouth and thereby relieves the symptoms of xerostomia.

Abstract: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.

Abstract: The new use of antagonists of the AMPA receptor complex and its physiologically compatible salts as pharmaceutical agents for prevention and treatment of Parkinson's disease as well as pharmaceutical agents, which contain these compounds, is described.